Karyopharm Therapeutics (KPTI) PT Raised to $7 at Wedbush, Following Earnings
Tweet Send to a Friend
Wedbush analyst David Nierengarten raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $7.00 (from $6.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
